The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Analysis of Patient-Reported Outcomes from Fox Insight, 2021Using Risk Scores to Link Molecular Mechanisms to Clinical Outcomes in Parkinson's Disease
Study Rationale:
The symptoms and course of Parkinson’s disease (PD) show remarkable variation from one person to another, indicating differences in the underlying disease process that may also be... -
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Using “Nanobodies” to Prevent Formation of Intracellular Alpha-synuclein Aggregates
Study Rationale: The aggregation of a structurally abnormal form of the protein alpha-synuclein appears to be responsible for the initiation and progression of Parkinson’s disease (PD). In previous...
-
Research Grant, 2024Assessment of Longitudinal Imaging Using Radiolabeled AV-133 in Early and Prodromal Parkinson’s Disease
Study Rationale: The clinical phase of Parkinson’s disease (PD) is preceded by a prodromal phase of progressing neurodegeneration that can last many years. Imaging markers such as radiolabeled AV-133...
-
Neuronal Synuclein Disease Endotypes 2024, 2025Identifying Biomarkers for the Common Mechanism Underlying the Disease Continuum from Parkinson’s Disease to Alzheimer’s Disease
Study Rationale: Disorders such as Parkinson’s disease (PD) and Alzheimer’s disease (AD) share many similarities in their pathology. In particular, both involve accumulation of amyloid-β and alpha...
-
Research Grant, 2024Quantification of Three Previously Identified Biomarkers of Progression in Stage 2/3 of Parkinson’s Disease
Study Rationale: Early indicators for Parkinson’s disease (PD), so-called biomarkers, are needed to identify subjects at risk during the earliest, prodromal stages of disease and to support clinical...
-
LRRK2 Cohort Consortium, 2012Parkinson’s Institute LRRK2 Cohort: Clinical Phenotype, Pre/Non-Motor and Environmental Risk Assessment
Objective/Rationale:
The objective of this award is to better understand the clinical symptoms of patients that carry the most common genetic risk factor for PD the LRRK2 G2019S variant and what role...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.